Scrip's Complete Guide to CNS Disorders

Scrip's Complete Guide to CNS Disorders

Therapeutic

A comprehensive overview of the global market for current and forthcoming CNS drugs, this report covers the major areas: Alzheimer's disease, Parkinson's disease, depression, schizophrenia and anxiety. Six volumes supply you with invaluable information on CNS drugs in R&D and the global market for CNS therapies.

Access:

Extensive R&D information on over 150 products in clinical trials for CNS disorders
R&D details for over 200 drugs in preclinical research
Relative market share of products and sales forecasts to 2002 for each disease
18 top company profiles
Sales figures for the top 30 CNS drugs currently on the market

Each major disease area is covered in a separate volume containing definitions, pathogenesis, risk factors and epidemiology. The report also supplies descriptions of current treatments and information on their advantages and disadvantages.

Profiles of the 18 companies most active in the CNS field allow you to undertake accurate competitor analysis - and evaluate opportunities for strategic collaborations.

PUBLISHED: AUGUST 1999
REF: BS1023E
PAGES: 600+
PRICE: Complete six-volume set �990/$1,995/�238,000

For more information or details on individual volume pricing, please contact our Customer Helpdesk:
Tel +44 (0)20 8332 8965/66
Fax +44 (0)20 8332 8992

CONTENTS
LIST OF TABLES
EXECUTIVE SUMMARY
METHODOLOGY
ABBREVIATIONS
GLOSSARY

CHAPTER 1 INTRODUCTION
1.1 Background
1.2 Definitions
1.2.1 Panic disorder
1.2.2 Phobia
1.2.2.1 Agoraphobia
1.2.2.2 Specific phobia
1.2.2.3 Social anxiety disorder
1.2.3 Generalised anxiety disorder
1.2.4 Obsessive-compulsive disorder
1.2.5 Post-traumatic stress disorder
1.2.6 Mixed depression and anxiety
1.2.7 Childhood anxiety
1.3 Pathogenesis
1.4 Symptoms
1.5 Prognosis
1.6 Opportunities for drug intervention
1.7 Aetiology
1.7.1 Hormonal factors and the stress response
1.7.2 Genetic risk factors
1.7.3 Risk factors
1.7.3.1 Age
1.7.3.2 Gender
1.7.3.3 Geographical region
1.7.3.4 Worldwide level of development
1.8 Epidemiology
1.8.1 Incidence
1.8.2 Prevalence
1.9 Trends in treatment and prevention
1.9.1 Present range of treatments
1.9.2 Additional non-drug treatments

CHAPTER 2 MARKETED DRUGS
2.1 Summary of drug classes
2.2 Benzodiazepines
2.2.1 Alprazolam
2.2.2 Clonazepam
2.2.3 Diazepam
2.2.4 Diazepam emulsion
2.2.5 Lorazepam
2.2.6 Lormetazepam
2.2.7 Midazolam
2.3 Serotonergic drugs
2.3.1 Monoamine oxidase inhibitors
2.3.1.1 Moclobemide
2.3.2 5-HT1A receptor partial antagonists (azaspirones)
2.3.2.1 Buspirone
2.3.3 Selective serotonin reuptake inhibitors
2.3.3.1 Citalopram
2.3.3.2 Fluoxetine
2.3.3.3 Fluvoxamine
2.3.3.4 Paroxetine
2.3.3.5 Sertraline
2.4 GABAergic agents
2.4.1 Rilmazafone
2.4.2 Tetrabamate
2.5 Dopaminergic agents
2.5.1 Sapropterin
2.6 Serotonin reuptake stimulants
2.6.1 Tianeptine
2.7 Miscellaneous agents
2.7.1 TJ-96
2.8 Opportunities for new drugs

CHAPTER 3 DRUGS IN DEVELOPMENT
3.1 Benzodiazepines
3.1.1 Y-23684
3.2 (-carbolines
3.2.1 Abecarnil
3.3 Serotonergic drugs
3.3.1 Monoamine oxidase inhibitors
3.3.1.1 KP157
3.3.2 5-HT1A receptor partial antagonists (azaspirones)
3.3.2.1 Alnespirone
3.3.2.2 Buspirone
3.3.2.3 DU-125530
3.3.2.4 Flesinoxan
3.3.2.5 F-11440 maleate
3.3.2.6 Lesopitron
3.3.2.7 MKC-242
3.3.2.8 NAD-299
3.3.2.9 Sunepitron
3.3.2.10 S-15535
3.3.2.11 U-93385
3.3.3 5-HT2 receptor antagonists
3.3.3.1 Deramciclane
3.3.3.2 Dotrazine
3.3.3.3 Nefazodone hydrochloride
3.3.3.4 SB-243213
3.3.3.5 SR-46349
3.3.4 Selective serotonin reuptake inhibitors
3.3.4.1 Fluoxetine
3.3.4.2 Fluvoxamine
3.3.4.3 Paroxetine
3.4 CholecystokininB receptor antagonists
3.4.1 CR-2945
3.4.2 Levetiracetam
3.5 Serotonin and noradrenaline reuptake inhibitors
3.5.1 Venlafaxine
3.6 Adrenergic agents
3.6.1 Dexmedetomidine
3.7 GABAergic agents
3.7.1 Gabapentin
3.7.2 NGD-91-2
3.7.3 NS-2710
3.7.4 Pagoclone
3.7.5 Pregabalin
3.8 Corticotrophin-releasing factor compounds
3.8.1 NBI-103 and NBI-30775
3.9 Neurokinin compounds
3.9.1 CGP-60829
3.9.2 Osanetant
3.10 Miscellaneous agents
3.10.1 AP-521
3.10.2 Etomidate
3.10.3 Lu28-179
3.10.4 LY-300164
3.10.5 LY-354740
3.11 Melatonin agonists
3.11.1 IPA
3.12 Future developments

REFERENCES

LIST OF TABLES
Table 1.1 Worldwide incidence and prevalence figures for generalised anxiety disorder in different age groups, 1995
Table 1.2 Worldwide incidence and prevalence figures for panic disorder in different age groups, 1995
Table 1.3 Worldwide incidence and prevalence figures for obsessive-compulsive disorder in different age groups, 1995
Table 1.4 Worldwide incidence and prevalence figures for post-traumatic stress disorder in different age groups, 1995
Table 1.5 Worldwide incidence and prevalence figures for generalised anxiety disorder in men and women, 1995
Table 1.6 Worldwide incidence and prevalence figures for panic disorder in men and women, 1995
Table 1.7 Worldwide incidence and prevalence figures for obsessive-compulsive disorder in men and women, 1995
Table 1.8 Worldwide incidence and prevalence figures for post-traumatic stress disorder in men and women, 1995
Table 1.9 Incidence and prevalence data for generalised anxiety disorder in different regions worldwide, 1995
Table 1.10 Incidence and prevalence data for panic disorder in different regions worldwide, 1995
Table 1.11 Incidence and prevalence data for obsessive-compulsive disorder in different regions worldwide, 1995
Table 1.12 Incidence and prevalence data for post-traumatic stress disorder in different regions worldwide, 1995
Table 1.13 Worldwide incidence and prevalence data for generalised anxiety disorder in areas with varying levels of development, 1995
Table 1.14 Worldwide incidence and prevalence data for panic disorder in areas with varying levels of development, 1995
Table 1.15 Worldwide incidence and prevalence data for obsessive-compulsive disorder in areas with varying levels of development, 1995
Table 1.16 Worldwide incidence and prevalence data for post-traumatic stress disorder in areas with varying levels of development, 1995
Table 1.17 Summary of WHO worldwide prevalence data for the anxiety-related disorders, 1995

Table 2.1 Summary of drug classes for treating anxiety
Table 2.2 Summary of companies with marketed first indication anxiolytics
Table 2.3 Summary of companies with marketed compounds for anxiety which are not first indication anxiolytics

Table 3.1 Summary of anxiolytics that have been registered or are awaiting registration for anxiety
Table 3.2 Summary of anxiolytics in clinical development for anxiety
Table 3.3 Summary of drugs in development for anxiety which are not first indication anxiolytics
Table 3.4 Summary of anxiolytics in preclinical development for anxiety

This volume, Anxiety, is part of a series forming
Scrip's Complete Guide to CNS Disorders. The other volumes in this series are:
Volume 1: Market Overview (BS1024)
Volume 2: Alzheimer's Disease and Other Dementias (BS1025)
Volume 3: Parkinson's Disease (BS1026)
Volume 4: Depression and Bipolar Disorder (BS1027)
Volume 5: Schizophrenia and Other Psychoses (BS1028)

EXECUTIVE SUMMARY
The worldwide market for anxiolytics was approximately $1.6 billion in 1997 and is predicted to increase to $1.9 billion in 2002. Anxiety accounted for 16% of the worldwide sales for psychiatry products in 1997, only 1% behind antipsychotics. With the predicted overall decline in sales of benzodiazepines by 2000, there is a great deal of scope for new and improved compounds. Older compounds may now be re-released in alternative formulations in order to maintain their market share (eg Buspar (buspirone) patch).

One of the major emerging trends is the scope for the newer antidepressant drugs to be used additionally for treating anxiety. The selective serotonin reuptake inhibitor antidepressants and the dual-acting serotonin/noradrenaline drugs such as venlafaxine (Effexor), sertraline (Zoloft), paroxetine (Paxil) and fluoxetine (Prozac) are beginning to gain additional indications for more than one anxiety-related disorder.

Even the indirectly-acting dopaminergic compound, bupropion (Wellbutrin), has been indicated for post-traumatic stress disorder (PTSD). Despite anxiety being an add-on for products indicated for depression, it is becoming a major therapeutic area in its own right, with the associated conditions, generalised anxiety disorder, obsessive-compulsive disorder, PTSD and panic disorder gaining ground as individual disorders.

Drugs with alternative mechanisms of action are still in trials but could have potential for anxiety-related disorders. They include melatonin compounds, neurokinins, cholecystokininB receptor antagonists and corticotrophin-releasing factor compounds.

Co-morbid anxiety with depression or other psychiatric disorders is increasingly becoming an area of interest. The apparent non-specific treatment response between the subtypes of the major disease areas suggests that certain types of anxiety and certain types of depression are either: different expressions of a similar disorder with a common neurobiological substrate; discrete diagnostic entities that respond to independent pharmacological effects of the same drugs; or a combination of the two. Research is increasing in this area and could open up new opportunities for other drugs which are already on the market.